{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:16:38Z","timestamp":1790813798179,"version":"4.1.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Center of Competences in Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Erythropoietic protoporphyria (EPP) is a rare genetic disease in which patients experience acute phototoxic reactions after sunlight exposure. It is caused by a deficiency in ferrochelatase (FECH) in the heme biosynthesis pathway. Most patients exhibit a loss-of-function mutation in trans to an allele bearing a SNP that favors aberrant splicing of transcripts. One viable strategy for EPP is to deploy splice-switching oligonucleotides (SSOs) to increase FECH synthesis, whereby an increase of a few percent would provide therapeutic benefit. However, successful application of SSOs in bone marrow cells is not described. Here, we show that SSOs comprising methoxyethyl-chemistry increase FECH levels in cells. We conjugated one SSO to three prototypical targeting groups and administered them to a mouse model of EPP in order to study their biodistribution, their metabolic stability and their FECH splice-switching ability. The SSOs exhibited distinct distribution profiles, with increased accumulation in liver, kidney, bone marrow and lung. However, they also underwent substantial metabolism, mainly at their linker groups. An SSO bearing a cholesteryl group increased levels of correctly spliced FECH transcript by 80% in the bone marrow. The results provide a promising approach to treat EPP and other disorders originating from splicing dysregulation in the bone marrow.<\/jats:p>","DOI":"10.1093\/nar\/gkaa229","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:14:26Z","timestamp":1586445266000},"page":"4658-4671","source":"Crossref","is-referenced-by-count":26,"title":["Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria"],"prefix":"10.1093","volume":"48","author":[{"given":"Fran\u00e7ois","family":"Halloy","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavithra\u00a0S","family":"Iyer","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"\u0106wiek","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ghidini","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Barman-Aks\u00f6zen","sequence":"first","affiliation":[{"name":"Institute of Laboratory Medicine, Triemli Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wildner-Verhey\u00a0van\u00a0Wijk","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre P A","family":"Theocharides","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth\u00a0I","family":"Minder","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Triemli Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Schneider-Yin","sequence":"first","affiliation":[{"name":"Institute of Laboratory Medicine, Triemli Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-134X","authenticated-orcid":false,"given":"Daniel","family":"Sch\u00fcmperli","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4160-7135","authenticated-orcid":false,"given":"Jonathan","family":"Hall","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"2020051611185228900_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-4-19","article-title":"Erythropoietic protoporphyria","volume":"4","author":"Lecha","year":"2009","journal-title":"Orphanet. J. Rare. Dis."},{"key":"2020051611185228900_B2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/blood.V93.6.2105.406k28_2105_2110","article-title":"Inheritance in erythropoietic Protoporphyria: A common Wild-Type ferrochelatase allelic variant with low expression accounts for clinical manifestation","volume":"93","author":"Gouya","year":"1999","journal-title":"Blood"},{"key":"2020051611185228900_B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng809","article-title":"The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH","volume":"30","author":"Gouya","year":"2002","journal-title":"Nat. Genet."},{"key":"2020051611185228900_B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","article-title":"Porphyria and kidney diseases","volume":"11","author":"Pallet","year":"2018","journal-title":"Clin. Kidney J."},{"key":"2020051611185228900_B5","first-page":"19","article-title":"The porphyrias: advances in diagnosis and treatment","volume":"2012","author":"Balwani","year":"2012","journal-title":"ASH Educ. Program Book"},{"key":"2020051611185228900_B6","first-page":"1009","article-title":"Liver disease in erythropoietic protoporphyria: insights and implications for management","volume":"56","author":"Anstey","year":"2007","journal-title":"Gut"},{"key":"2020051611185228900_B7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/301870","article-title":"Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria","volume":"62","author":"R\u00fcfenacht","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"2020051611185228900_B8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ajhg.2014.02.010","article-title":"Antisense oligonucleotide-Based therapy in human erythropoietic protoporphyria","volume":"94","author":"Oustric","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"2020051611185228900_B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ajhg.2018.12.021","article-title":"Erythroid-progenitor-targeted gene therapy using bifunctional TFR1 ligand-peptides in human erythropoietic protoporphyria","volume":"104","author":"Mirmiran","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"2020051611185228900_B10","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","article-title":"Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides","volume":"90","author":"Dominski","year":"1993","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2020051611185228900_B11","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"2020051611185228900_B13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"2020051611185228900_B14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hlca.19950780219","article-title":"Ein neuer Zugang zu 2\u2032-O-Alkylribonucleosiden und eigenschaften deren oligonucleotide","volume":"78","author":"Martin","year":"1995","journal-title":"Helv. Chim. Acta"},{"key":"2020051611185228900_B15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"2020051611185228900_B16","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1093\/nar\/gks861","article-title":"Target mRNA inhibition by oligonucleotide drugs in man","volume":"40","author":"Lightfoot","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nbt759","article-title":"Systemically delivered antisense oligomers upregulate gene expression in mouse tissues","volume":"20","author":"Sazani","year":"2002","journal-title":"Nat. Biotech."},{"key":"2020051611185228900_B18","doi-asserted-by":"crossref","first-page":"a011601","DOI":"10.1101\/cshperspect.a011601","article-title":"Erythropoiesis: Development and differentiation","volume":"3","author":"Dzierzak","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2020051611185228900_B19","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"2020051611185228900_B20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1242\/dmm.027755","article-title":"Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice","volume":"10","author":"Barman-Aks\u00f6zen","year":"2017","journal-title":"Dis. Models Mech."},{"key":"2020051611185228900_B21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u2018antagomirs\u2019","volume":"438","author":"Kr\u00fctzfeldt","year":"2005","journal-title":"Nature"},{"key":"2020051611185228900_B22","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/nar\/gkm024","article-title":"Specificity, duplex degradation and subcellular localization of antagomirs","volume":"35","author":"Kr\u00fctzfeldt","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat. Biotech."},{"key":"2020051611185228900_B24","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1634\/stemcells.22-6-1030","article-title":"A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells","volume":"22","author":"Nowakowski","year":"2004","journal-title":"Stem Cells"},{"key":"2020051611185228900_B25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/nar\/gky1232","article-title":"Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways","volume":"47","author":"Osborn","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B26","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/nar\/gkz354","article-title":"Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle","volume":"47","author":"Prakash","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B27","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1093\/nar\/gkt515","article-title":"Whole-body scanning PCR; a highly sensitive method to study the biodistribution of mRNAs, noncoding RNAs and therapeutic oligonucleotides","volume":"41","author":"Boos","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1039\/C6CC08473G","article-title":"Synthesis and cellular activity of stereochemically-pure 2[prime or minute]-O-(2-methoxyethyl)-phosphorothioate oligonucleotides","volume":"53","author":"Li","year":"2017","journal-title":"Chem. Commun."},{"key":"2020051611185228900_B29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-4939-8651-4_5","article-title":"Tips to design effective splice-switching antisense oligonucleotides for exon skipping and exon inclusion","volume":"1828","author":"Maruyama","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"2020051611185228900_B30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-61779-767-5_8","volume-title":"Exon Skipping: Methods and Protocols","author":"Aartsma-Rus","year":"2012"},{"key":"2020051611185228900_B31","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/nar\/gky249","article-title":"Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice","volume":"46","author":"Sinha","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"2020051611185228900_B33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2017.0693","article-title":"The Effects of 2\u2032-O-Methoxyethyl oligonucleotides on renal function in humans","volume":"28","author":"Crooke","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B34","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1093\/nar\/gkw1109","article-title":"Modulation of nonsense mediated decay by rapamycin","volume":"45","author":"Martinez-Nunez","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bcmd.2013.05.008","article-title":"Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.)","volume":"51","author":"Barman-Aks\u00f6zen","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"2020051611185228900_B36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijc.2910230202","article-title":"K562\u2014a human erythroleukemic cell line","volume":"23","author":"Andersson","year":"1979","journal-title":"Int. J. Cancer"},{"key":"2020051611185228900_B37","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gkp215","article-title":"Human splicing finder: an online bioinformatics tool to predict splicing signals","volume":"37","author":"Desmet","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B38","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.0801692105","article-title":"RNA landscape of evolution for optimal exon and intron discrimination","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2020051611185228900_B39","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1093\/nar\/gkv275","article-title":"Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903+469T&gt;C MTRR mutation corrects splicing and restores enzyme activity in patient cells","volume":"43","author":"Palhais","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/nat.2018.0725","article-title":"Improving siRNA delivery in vivo through lipid conjugation","volume":"28","author":"Osborn","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B41","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1038\/mtna.2012.27","article-title":"Pharmacokinetics and toxicity in rats and monkeys of coDbait: A therapeutic Double-stranded DNA oligonucleotide conjugated to cholesterol","volume":"1","author":"Schlegel","year":"2012","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"2020051611185228900_B42","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1021\/ol201690b","article-title":"Maleimide-dimethylfuran exo adducts: effective maleimide protection in the synthesis of oligonucleotide conjugates","volume":"13","author":"S\u00e1nchez","year":"2011","journal-title":"Org. Lett."},{"key":"2020051611185228900_B43","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1039\/c2ob26514a","article-title":"Easy introduction of maleimides at different positions of oligonucleotide chains for conjugation purposes","volume":"10","author":"S\u00e1nchez","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"2020051611185228900_B44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jps.10473","article-title":"Tissue disposition of 2\u2032-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys","volume":"93","author":"Yu","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"2020051611185228900_B45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/oli.2010.0252","article-title":"In vitro metabolic stabilities and metabolism of 2\u2032-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates","volume":"20","author":"Baek","year":"2010","journal-title":"Oligonucleotides"},{"key":"2020051611185228900_B46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2013.05.050","article-title":"The thiol pool in human plasma: the central contribution of albumin to redox processes","volume":"65","author":"Turell","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"2020051611185228900_B47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody\u2013drug conjugates: current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"key":"2020051611185228900_B48","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.4155\/bio-2017-0145","article-title":"Quantitative analysis of imetelstat in plasma with LC\u2013MS\/MS using solid-phase or hybridization extraction","volume":"9","author":"Dillen","year":"2017","journal-title":"Bioanalysis"},{"key":"2020051611185228900_B49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2017.0680","article-title":"Effect of chemical modifications on aptamer stability in serum","volume":"27","author":"Kratschmer","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B50","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.4049\/jimmunol.176.6.3652","article-title":"Modification of MyD88 mRNA splicing and inhibition of IL-1\u03b2 signaling in cell culture and in mice with a 2\u2032-O-methoxyethyl-modified oligonucleotide","volume":"176","author":"Vickers","year":"2006","journal-title":"J. Immunol."},{"key":"2020051611185228900_B51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nchembio.939","article-title":"Synthetic oligonucleotides recruit ILF2\/3 to RNA transcripts to modulate splicing","volume":"8","author":"Rigo","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"2020051611185228900_B52","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","article-title":"Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100","volume":"77","author":"Yu","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"2020051611185228900_B53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-3148-4_8","volume-title":"RNA Imaging: Methods and Protocols","author":"Boos","year":"2016"},{"key":"2020051611185228900_B54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1039\/C5CC07478A","article-title":"Site-specific conjugation of drug-like fragments to an antimiR scaffold as a strategy to target miRNAs inside RISC","volume":"52","author":"Brunschweiger","year":"2016","journal-title":"Chem. Commun. (Camb.)"},{"key":"2020051611185228900_B55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2020051611185228900_B56","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B57","first-page":"923","article-title":"Pharmacokinetic properties of several novel oligonucleotide analogs in mice","volume":"277","author":"Crooke","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2020051611185228900_B58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2017.0693","article-title":"The effects of 2\u2032-O-methoxyethyl oligonucleotides on renal function in humans","volume":"28","author":"Crooke","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrg.2015.3","article-title":"RNA mis-splicing in disease","volume":"17","author":"Scotti","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"2020051611185228900_B60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40348-018-0081-6","article-title":"The potential of antisense oligonucleotide therapies for inherited childhood lung diseases","volume":"5","author":"Martinovich","year":"2018","journal-title":"Mol Cell Pediatr"},{"key":"2020051611185228900_B61","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1093\/nar\/gky921","article-title":"Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment","volume":"46","author":"Mogilevsky","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2020051611185228900_B62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2012.264","article-title":"Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo","volume":"21","author":"Disterer","year":"2013","journal-title":"Mol. Ther."},{"key":"2020051611185228900_B64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/nat.2019.0824","article-title":"Using a state-of-the-art toolbox to evaluate molecular and functional readouts of antisense oligonucleotide-Induced exon skipping in mdx mice","volume":"30","author":"Datson","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B65","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4155\/bio-2017-0017","article-title":"Quantitative determination of a siRNA (AD00370) in rat plasma using peptide nucleic acid probe and HPLC with fluorescence detection","volume":"9","author":"Tian","year":"2017","journal-title":"Bioanalysis"},{"key":"2020051611185228900_B66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2019.0810","article-title":"Nuclear and cytoplasmatic quantification of unconjugated, label-free locked nucleic acid oligonucleotides","volume":"30","author":"Pendergraff","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"2020051611185228900_B67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40291-019-00438-6","article-title":"Leading RNA interference therapeutics. Part 2: Silencing delta-aminolevulinic acid synthase 1, with a focus on givosiran","volume":"24","author":"de\u00a0Paula\u00a0Brand\u00e3o","year":"2019","journal-title":"Mol. Diag. Ther."},{"key":"2020051611185228900_B68","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"2020051611185228900_B69","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/48\/9\/4658\/33221338\/gkaa229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/48\/9\/4658\/33221338\/gkaa229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T17:10:28Z","timestamp":1589649028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/48\/9\/4658\/5822958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa229","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.02.14.949297","asserted-by":"object"}]},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,21]]},"published":{"date-parts":[[2020,4,20]]}}}